美国低危患者经导管主动脉瓣置换术的真实世界结局:STS/ACC TVT注册报告
基于STS/ACC TVT注册中2020年1月至2024年3月的心脏团队判定低危、三叶瓣重度症状性主动脉瓣狭窄行TAVR的患者,评估30天和1年结局。试验合格人群1年死亡3.1%、卒中2.4%、92%存活且健康;真实世界结局优于试验合格标准但不良事件高于已发表临床试验数据,可能因合并症负担更重和基线KCCQ评分更低。
要点
- 心脏团队判定低危TAVR患者1年死亡4.6%、卒中2.6%、90%存活且健康。
- 符合低危试验标准的患者1年死亡3.1%、卒中2.4%、92%存活且健康。
- 1年死亡的独立预测因素包括房颤、非股动脉入路和基线KCCQ评分较低。
核心结论
- 真实世界中符合低危试验标准的TAVR患者1年结局优秀,但不良事件高于已发表临床试验数据。
- 差异可能归因于合并症负担更重和基线KCCQ评分更低。
研究设计与样本
- 基于STS/ACC TVT注册的回顾性队列研究,纳入2020年1月至2024年3月心脏团队判定低危、三叶瓣重度症状性主动脉瓣狭窄行TAVR的患者。
主要发现
- 心脏团队判定低危总体人群:30天死亡0.8%、卒中1.5%、新永久起搏器8.4%;1年死亡4.6%、卒中2.6%、90%存活且健康。
- 试验合格人群:30天死亡0.6%、卒中1.4%、新永久起搏器8.0%;1年死亡3.1%、卒中2.4%、92%存活且健康。
- 1年死亡的多变量预测因素包括房颤、非股动脉入路和基线KCCQ评分较低。
临床怎么用
- 真实世界低危TAVR结局数据可用于与患者沟通预期结局和健康状况。
- 应关注房颤、非股动脉入路和基线KCCQ评分较低等高危因素以优化患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption. METHODS: We identified heart team-designated low-risk patients undergoing TAVR for trileaflet severe, symptomatic aortic stenosis in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Registry, as well as a subset of patients who met low-risk trial inclusion and exclusion criteria, from January 2020 to March 2024. Outcomes (mortality, stroke, new pacemaker, and "alive and well," defined as alive at 1 year with Kansas City Cardiomyopathy Questionnaire score ≥60 and ≤10-point decrease from baseline) at 30 days and 1 year were assessed. Multivariable models were developed to assess predictors of death and stroke within 1 year after TAVR. RESULTS: Among 383 030 patients who underwent TAVR during the study period, 108 407 (28%) were designated low-risk by the heart team, and 68 194 (18%) met other study inclusion and exclusion criteria. Of these, 62% (n=42 093) would have been eligible for the low-risk trials. In the overall heart team-designated low-risk population, 30-day outcomes included 0.8% mortality, 1.5% stroke, and 8.4% new permanent pacemaker requirement; 1-year outcomes included 4.6% mortality, 2.6% stroke, and 90% alive and well. In the trial-eligible population, 0.6% mortality, 1.4% stroke, and 8.0% new permanent pacemaker requirement had occurred by 30 days; values at 1 year included 3.1% mortality, 2.4% stroke, and 92% alive and well. Notable multivariable predictors of 1-year mortality were atrial fibrillation, nontransfemoral access, and lower baseline Kansas City Cardiomyopathy Questionnaire score. CONCLUSIONS: One-year outcomes among real-world trial-eligible patients are excellent, but adverse events are higher compared with published clinical trial data, likely because of greater comorbidity burden and lower baseline Kansas City Cardiomyopathy Questionnaire score. These data can help inform expected outcomes and health status after low-risk TAVR.
引用
- Vekstein AM, Wegermann ZK, Manandhar P, et al. Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry. Circulation. 2025. PMID: 40177743. doi:10.1161/CIRCULATIONAHA.124.071838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。